Skip to content

Seminar Title

 

Synergy Satellite: Evidence and pharmacovigilance of monoclonal antibody reference and biosimilar products (sponsored by an educational grant from Roche)

Affiliation

Karolinska Institute, Stockholm

Country

Sweden

1. Current Status, Position

Mr Mellstedt is Professor of Oncologic Biotherapy at the Karolinska Institute, CancerCentre Karolinska at the Karolinska University Hospital Solna, Stockholm.

2. Education

  • 1996-1999: MD, PhD at the Karolinska Institute, Professor of Experimental Oncology at Uppsala University and Academic Hospital.
  • Since 1999: Professor of Oncologic Biotherapy at Karolinska Insitute.
  • Board certified in Internal Medicine, Hematology and Oncology.
  • 2004-2009: ESMO President.

3. Research Area

  • Immune biology of B-lymphoproliferative diseases and gastrointestinal cancer. 
  • Development of monoclonal antibody therapy and cancer vaccine in malignant B-cell disorders, colorectal and pancreatic carcinoma. 
  • Development of therapeutic monoclonal antibodies and thyrosine kinase receptors against the RTK ROR. 
  • He has published more than 500 scientific articles within these areas and written numerous chapters in text books.
 
Conflict of interest: Håkan Mellstedt has received honoraria from Abbvie, Amgen, Bio-Sweden, Boeringer-Ingelheim, Hospira, Roche and research grants from Merck GmBH.
Håkan Mellstedt has served on ad hoc SAB for Abbvie, Amgen, Boeringer-Ingelheim, Hospira.


×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.